The Ministry of Health, Labor and Welfare (MHLW) will begin accepting the online submission of new drug applications (NDAs) as well as other documents related to pharmaceuticals and medical devices, beginning on July 1. The MHLW started accepting online submissions…
To read the full story
Related Article
- Online Submissions for Generic Approval to Start from January
November 14, 2022
- Online NDA Submission Starts in Japan: MHLW/PMDA
July 4, 2022
REGULATORY
- MHLW Issues Q&A on Conditional Approval System
May 1, 2026
- Panel Backs Proposal to Allow Antibody Drugs Like Beyfortus in NIP
May 1, 2026
- METI Clarifies Naphtha Comments, Reaffirms Medical Priority
April 30, 2026
- Japan Minister Rules Out Full Self-Pay for OTC-Like Drugs
April 30, 2026
- Govt’s Bio-WG Wraps Up Biopharma Investment Roadmap Draft
April 30, 2026
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…





